CLB earnings analysis
What we found in CLB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Core Laboratories' Q1 2026 results showed a significant revenue decline to $121.8 million, down 12% sequentially and slightly down 1% year-over-year. EPS was reported at $0.06, falling short of estimates, marking a 72% drop from the previous quarter. Management cited geopolitical challenges and adverse weather conditions as key factors affecting performance, although they remained optimistic about long-term growth prospects in the energy market.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline
- Q1 2026 revenue decreased to $121.8 million, a 12% drop sequentially and 1% down versus Q1 2025.
- Significant EPS Drop
- Reported EPS of $0.06 missed estimates by $0.04, representing a 72% decrease compared to the prior quarter.
- Service Revenue Impact
- Service revenue from the Reservoir Description segment slightly rose 1% year-over-year to $81.9 million, but fell 11% sequentially.
- Free Cash Flow Minimized
- Free cash flow was $0.5 million, a significant decline from $3.9 million year-over-year.
- High Operating Expenses
- Operating expenses increased to $102.1 million, up 3% year-over-year largely due to geopolitical impacts.
- Debt to EBITDA Ratio Improvement
- Debt to EBITDA ratio improved slightly to 1.34:1 from 1.37:1 in Q4 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Geopolitical Instability
- Ongoing conflicts in the Middle East, especially involving Iran, have disrupted operations and raised commodity price volatilities.
- Increased Operating Costs
- Higher shipping and operational costs due to geopolitical tensions and unfavorable foreign exchange rates affected profitability.
- Declining Demand
- Lower activity levels in international markets led to decreased client demand, impacting service offerings and revenues.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.06
- Operating margin
- 2%
- Segment
- Reservoir Description: $81.9M
- Segment
- Production Enhancement: $39.9M
What they said about what is next.
Management maintains a long-term optimistic outlook despite short-term geopolitical challenges.
The filing reads worse than the one before it.
What came before.
- 10-K · March 23, 2026
- Core Laboratories describes a technology- and IP-driven strategy focused on proprietary reservoir description and production enhancement services, international expansion and selective acquisitions. Revenue edged higher…
- 10-Q · October 23, 2025
- Core Laboratories reported Q3 revenue of $134.521 million, essentially flat year-over-year (+$0.124 million) with margin expansion (gross ~22.0%, operating ~15.6%) and diluted EPS attributable to Core Laboratories of…
- 10-K · February 13, 2025
- Core Laboratories reported consolidated revenue of $523.848 million for the year ended December 31, 2024, up from $509.790 million in 2023 and $489.735 million in 2022. The company emphasizes growth via proprietary…
- 10-Q · October 24, 2024
- Core Laboratories reported quarterly revenue of $134,397,000 (Q3 2024), up versus Q3 2023 ($125,343,000) and the prior quarter, with operating income of $19,803,000 and diluted EPS of $0.25. Gross margin compressed to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CLB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever